NAD Case Reopened, But Fungi-Nail Marketer Fails Again With ‘#1 Pharmacist Recommended’ Claim
New Jersey-based Arcadia Consumer Healthcare, Inc., succeeded in reopening a 2018 National Advertising Division case involving its ‘#1 Pharmacist Recommended’ claim for the Fungi-Nail line, but failed again to convince the NAD that survey findings justify the claim.
You may also be interested in...
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
Three years ago, the Kerasal fungal nail brand brought a challenge to the National Advertising Division that decimated claims for competing Fungi-Nail products and got federal agencies involved. The shoe is now on the other foot, as the NAD agrees with Fungi-Nail that a slew of Kerasal claims should be discontinued.
Recent personal-care product launches show companies innovating in emerging frontiers and hazily regulated territory with probiotic oral care, over-the-counter fungal nail care and nasal antiseptic care. Elsewhere, sensitive skin specialist Cetaphil introduces ultra-moisturizing products, and Nestle Health Sciences’ Atrium Innovations launches a line of nutritional supplements for skin, hair and nail health.